KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed FCF Margin for 7 consecutive years, with 26.75% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 7686.0% year-over-year to 26.75%, compared with a TTM value of 3.29% through Dec 2025, up 382.0%, and an annual FY2025 reading of 3.29%, up 382.0% over the prior year.
  • FCF Margin was 26.75% for Q4 2025 at Esperion Therapeutics, up from 4.91% in the prior quarter.
  • Across five years, FCF Margin topped out at 39.03% in Q1 2024 and bottomed at 1116.42% in Q1 2021.
  • Average FCF Margin over 5 years is 182.37%, with a median of 105.44% recorded in 2023.
  • Peak annual rise in FCF Margin hit 267461bps in 2021, while the deepest fall reached -18359bps in 2021.
  • Year by year, FCF Margin stood at 374.69% in 2021, then soared by 40bps to 225.7% in 2022, then soared by 49bps to 114.9% in 2023, then skyrocketed by 56bps to 50.11% in 2024, then soared by 153bps to 26.75% in 2025.
  • Business Quant data shows FCF Margin for ESPR at 26.75% in Q4 2025, 4.91% in Q3 2025, and 38.14% in Q2 2025.